imatinib_mesylate: profile and news
Power3 Medical Using Biomarkers for Early Detection of ... 16 May 2006
...which determines if patients with Chronic Myelogenous Leukemia (CML) are resistant to - or are likely to build resistance to - imatinib mesylate (Gleevec(R ... - Genetic Engineering News,
New Study Shows Initial Treatment With 800 mg/day Imatinib ... May 15, 2006
EAST HANOVER, GERMANY -- May 15, 2006 -- A higher, investigational starting dose of Gleevec® (imatinib mesylate)* tablets can improve outcomes for high-risk ... - DG News
Five years after approval, Gleevec underscores the promise of ... May 9, 2006
EAST HANOVER, NJ, May 10 /PRNewswire/ -- Marking an important milestone since its first approval in May 2001, Gleevec® (imatinib mesylate) tablets,* has ... - Yahoo! News (press release)
Five Years After Approval, Gleevec Underscores The Promise Of ... May 12, 2006
Marking an important milestone since its first approval in May 2001, Gleevec(R) (imatinib mesylate) tablets,* has become the first oncology drug to be ... - Medical News Today (press release),
Gleevec® May Inhibit Bone Growth May 12, 2006
Although Gleevec® (imatinib mesylate) has improved survival for patients with chronic myeloid leukemia, a small study suggests that Gleevec may interfere with ... - Cancer Consultants (press release),
Imatinib Treatment Linked to Hypophosphatemia, Altered Bone ... May 11, 2006
NEW YORK MAY 10, 2006 (Reuters Health) - Treatment with imatinib mesylate for chronic myelogenous leukemia (CML) or gastrointestinal stromal tumors (GIST) may ... - Cancerpage.com,
Altered Bone and Mineral Metabolism in Patients Receiving Imatinib May 10, 2006
Background Imatinib mesylate inhibits several tyrosine kinases, including BCR-ABL, the C-KIT receptor, and the platelet-derived growth factor receptors and ... - New England Journal of Medicine (subscription),
Pfizer receives positive EU opinion for Sutent May 2, 2006
...also granted for gastrointestinal stromal tumor (GIST), a rare stomach and intestinal cancer, in patients who are resistant or intolerant to imatinib mesylate. ... - Pharmaceutical Business Review
NCCN Announces Important Updates to Soft Tissue Sarcoma Guidelines May 10, 2006
...tyrosine kinase (RTK) inhibitor, for the treatment of gastrointestinal stromal tumor (GIST) after disease progression on or intolerance to imatinib mesylate. ... - Business Wire (press release),
MSF Supports Opposition To Gilead's Tenofovir Patent Application ... May 10, 2006
Cancer patients and generic drug manufacturers recently opposed a Novartis patent application for Gleevec (imatinib mesylate), an anti-cancer drug, on the ... - Doctors Without Borders,
At High Doses Gleevec May Increase Risk of Bone Wasting May 12, 2006
NEW YORK, May 11 — Gleevec (imatinib mesylate), given for chronic myelogenous leukemia (CML) and gastrointestinal stromal tumors (GIST), may inhibit bone ... - MedPage Today,
(c) 2006 Business Wire Apr 24, 2006
...proteomic platform, has 19 identified biomarkers that indicate which patients are resistant to - or will build resistance to - imatinib mesylate (Gleevec(R ... - Houston Chronicle,
Cipla opposes patent application on bird-flu drug May 1, 2006
The Indian Patent Office had rejected Novartis' claim for a patent on imatinib mesylate, its cancer drug sold under the brand name Gleevec. - Hindu Business Line,
Monitoring Cancer Treatment Response With PET, Part 1 Apr 27, 2006
FDG allowed differentiation of responders and nonresponders to imatinib mesylate (Gleevac, Novartis), a selective tyrosine kinase inhibitor, in patients who ... - Medscape (subscription)
CHMP Grants First Conditional Marketing Recommendation To Pfizer's ... May 1, 2006
...for the treatment of unresectable and/or metastatic malignant gastrointestinal stromal tumours (GIST) after failure of imatinib mesylate treatment due to ... - UroToday,
Novartis Completes Submissions In US And Europe For Glivec As ... Apr 17, 2006
...announced today that it has submitted applications in the United States and Europe for Glivec® (imatinib) Known as Gleevec® (imatinib mesylate) Tablets in ... - Medical News Today (press release),
Pfizer's Sutent closer to approval in EU Apr 28, 2006
...alpha or interleukin-2-based therapy, and for the treatment of gastrointestinal stromal tumor patients who are resistant or intolerant to imatinib mesylate. ... - United Press International
